Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism - Wikidata - thesis-toulmin - TriplyDB

Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism

Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism

http://www.wikidata.org/entity/Q35744474

about

Hypoparathyroidism: Replacement Therapy with Parathyroid Hormone PTH receptor-1 signalling-mechanistic insights and therapeutic prospects Therapy of hypoparathyroidism by replacement with parathyroid hormone Autosomal Dominant Hypocalcemia (Hypoparathyroidism) Types 1 and 2 Long-term follow-up of patients with hypoparathyroidism Epidemiology and Diagnosis of Hypoparathyroidism.Management of Hypoparathyroidism: Present and Future.Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism.PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy Hypoparathyroidism after Roux-en-Y gastric bypass--a challenge for clinical management: a case report Parathyroid hormone therapy for hypoparathyroidism Use of parathyroid hormone in hypoparathyroidism.PTH(1-84) replacement therapy for the treatment of hypoparathyroidism.International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors.Endosomal generation of cAMP in GPCR signaling.Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety.Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH The effect of PTH(1-84) on quality of life in hypoparathyroidism.Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism Mini-review: new therapeutic options in hypoparathyroidism.Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.Review of Hypoparathyroidism.PTH replacement therapy of hypoparathyroidism.Causes, mechanisms and management of paediatric osteoporosis.Activating calcium-sensing receptor gene variants in children: a case study of infant hypocalcaemia and literature review.Impact of recombinant PTH on management of hypoparathyroidism: a systematic review.Recombinant PTH therapy for severe hypoparathyroidism after kidney transplantation in pre-transplant parathyroidectomized patients: review of the literature and a case report.Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.Hypoparathyroidism and pseudohypoparathyroidism: etiology, laboratory features and complications.Normocalcaemic hypoparathyroidism: prevalence and effect on bone status in older women. The OPUS study.Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.Efficacy of Teriparatide in Patients with Hypoparathyroidism: A Prospective, Open-label Study Repurposing a novel parathyroid hormone (PTH) analog to treat hypoparathyroidism.The effect of continuous subcutaneous recombinant PTH (1-34) infusion during pregnancy on calcium homeostasis - a case report.Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial.Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.Sustained release of parathyroid hormone via in situ cross-linking gelatin hydrogels improves the therapeutic potential of tonsil-derived mesenchymal stem cells for hypoparathyroidism.Developments in rare bone diseases and mineral disorders.

P2860

Q26782156-08040813-9E4D-4E2D-A675-82BDCBDFE815 Q26798005-C64EC72F-CEC1-414E-ADEC-4D26E9AB0315 Q26828582-52161E9F-63E3-4A8B-94F0-A3E057373604 Q28076495-491A0882-3AEE-40B9-A755-BE052F6FCE95 Q28276548-DBB2AB89-986D-4F2A-AE78-5E48306535D1 Q33570602-66CDF4C1-A974-4E52-B6B2-B8D825BEF8F2 Q33570607-38E50BF3-C063-42DA-8D76-B99DD7A0606F Q34240782-6C9F0B6C-29F0-405F-BF29-83361D5DC80E Q34284783-5A881404-FA48-422E-A304-51E7014326B1 Q34512519-397B5679-36EB-4572-9DA4-C5811A7BB4C0 Q35014795-A59E8D67-D384-45EE-B52C-351534AC2108 Q35043115-86770A9B-46BE-404B-BA93-A5E0008F4B66 Q35100381-001AC8AD-8234-4211-99E7-5A901211BA68 Q35383816-F5E030C4-9CDE-48C4-8ACD-ADAF48B6D059 Q35563982-264D3B3D-7CCC-4414-976B-38479E3B4532 Q36103534-B7E7B9A6-C013-4E18-AC2E-22C495DE452B Q36508951-7726A1B4-EB38-4692-AE27-A366CB76B21B Q36762546-8C12C580-3C5C-4B21-99F0-5359C4895313 Q36885818-E33EFFC5-021C-401A-93C9-1C790F1A8A9E Q36889099-0C913770-73D1-4C94-A1D5-2808619535EF Q36949203-2AB42367-FF2F-493B-AE88-A23A872B1D0D Q37057936-9B0A12C5-4BA1-4CBF-9AAD-9265FA944C55 Q37430684-322146A9-3C83-4237-82A4-D0D6BE1C2090 Q37587224-79A8AD42-F026-49CC-9C89-FA0AA4D5DA2C Q38062849-513813BC-778C-485E-BF45-DC53D9E1A283 Q38099517-BBB9BDB5-A21C-47F9-ADBA-9455D616CFB0 Q38231338-45F9906D-B9C1-4430-A819-C9E054C7BD05 Q38310672-313C9F38-7873-49EB-9FC1-33864F8FF5DE Q38578932-2C743DA5-DF8E-4717-B77B-53E236EAB9EC Q38884368-564111F7-B9BB-4398-BBBF-1101FA4CCBEE Q39143531-12FD4722-C4D3-4E17-B824-13E8515D3D76 Q41496981-D84DEE7E-C0BA-4F1A-99FA-C307AB3AC30A Q42014841-2D6C014F-86A4-45C4-A55E-E44C196C9F9E Q42161805-84F54315-42DB-4AAB-8345-5FBB6D2AA3AC Q42689961-5C7E3D8F-076B-4364-9365-F3D32569DAD7 Q43672500-349C4AC9-CAB2-4960-80A7-D8AB03B30240 Q48081325-90C443CF-51B7-4A76-97B9-F3E54247D121 Q48160184-C15F3BEF-3F92-448B-A57B-7CD1081FE1F3 Q48185872-578DB52A-589B-46C8-A175-CC887C6CF775 Q49413973-3EE66DF0-A9E1-4892-8985-89F16BD8F1A6

P2860

Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism

http://www.wikidata.org/entity/Q35744474

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Synthetic human parathyroid ho ...... of chronic hypoparathyroidism

@ast

Synthetic human parathyroid ho ...... of chronic hypoparathyroidism

@en

type

label

Synthetic human parathyroid ho ...... of chronic hypoparathyroidism

@ast

Synthetic human parathyroid ho ...... of chronic hypoparathyroidism

@en

prefLabel

Synthetic human parathyroid ho ...... of chronic hypoparathyroidism

@ast

Synthetic human parathyroid ho ...... of chronic hypoparathyroidism

@en

P1433

Q35744474-04BA5D47-C45D-4D6D-9B03-E238F3A84DFD

P1476

Q35744474-63058F30-9648-41FF-AE38-57BB98989B52

P2093

Q35744474-365EA88E-0F1C-4F66-8A81-56C035230299

Q35744474-38A70633-1938-4BE2-9F33-A984824DD744

Q35744474-414B57E8-3DD3-4646-8841-11E31B175C81

Q35744474-646F9714-1D5C-4272-B472-7EBA6FEBD8A4

Q35744474-B19630F7-8226-43C4-90B9-B9224DFEA51D

Q35744474-B1E75508-F107-4B8D-BB27-1DDC192D3525

Q35744474-E8CA09CB-F23C-4588-850F-19EE77182E96

P2860

Q35744474-1C4A0406-24B2-47FB-9057-FFF4B67BA371

Q35744474-1DA0B159-416E-494C-A712-613667BD3A42

Q35744474-337BB760-8576-47BF-99C8-9BF95ACD4C83

Q35744474-3544BF0D-7F0D-4A20-895C-07EB347A6DC2

Q35744474-3E146D9B-D343-425F-950C-119C75869F92

Q35744474-400433CE-0DA5-4B39-96C4-1BC77A78944F

Q35744474-40B3EC01-1018-4CC5-B20E-E7E0C80EE193

Q35744474-437ED01A-866D-4C6C-B288-5D85728FBC09

Q35744474-4D038E30-8A1C-44FD-8B53-445D69940BC6

Q35744474-770B320B-84E8-4CEC-8C64-DE25EC9D2446

P304

Q35744474-737D1543-8334-48FF-B80D-767720923C89

P31

Q35744474-EFC72608-3764-4FF8-8918-D068B993F515

P356

Q35744474-1E99CB69-84B9-4545-8EB8-E6F1E59F42A5

P407

Q35744474-3BA380D3-CBA4-47C1-9B42-F0DE3ECA21FE

P433

Q35744474-FC1955C5-9B8F-4517-B0A1-75E80A63A1F3

P478

Q35744474-C061C43F-FE1A-49FA-96F9-4C0DE97CFC67

P577

Q35744474-089B3278-44CC-4668-9FD2-1ABBEA10E8E1

P698

Q35744474-1CFB3B55-EBB7-435F-9F03-6BB6A3AE353B

P932

Q35744474-D3505A27-2857-44C7-B04D-9B345DDB9B30

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Synthetic human parathyroid ho ...... of chronic hypoparathyroidism

@en

P2093

Bo Zhang

http://www.w3.org/2001/XMLSchema#string

Donna Peterson

http://www.w3.org/2001/XMLSchema#string

Gordon B Cutler

http://www.w3.org/2001/XMLSchema#string

Joseph A Shrader

http://www.w3.org/2001/XMLSchema#string

Karen K Winer

http://www.w3.org/2001/XMLSchema#string

Michaele Smith

http://www.w3.org/2001/XMLSchema#string

Paul S Albert

http://www.w3.org/2001/XMLSchema#string

P2860

On analyzing circadian rhythms data using nonlinear mixed models with harmonic terms.

Statistical methods for detecting and comparing periodic data and their application to the nycthemeral rhythm of bodily harm: A population based study.

Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.

ATS statement: guidelines for the six-minute walk test.

Therapy of hypoparathyroidism with intact parathyroid hormone.

Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women.

Clinical practice. Hypoparathyroidism.

Dihydrotachysterol therapy for hypoparathyroidism: consequences of inadequate monitoring. Five cases and a review.

Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.

Tubular reabsorption of calcium in normal and hypercalciuric subjects

P304

391-399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2011-1908

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22090268

http://www.w3.org/2001/XMLSchema#string

P932

3275355

http://www.w3.org/2001/XMLSchema#string